Glycogen Storage Disease Type Ib in the Compound Heterozygous State: Case Report
Nikol P. Shimkova,
Mariya A. Snegurenko,
Eva Yunkevich,
Nataliya V. Klimina,
Anastasiya A. Shepina,
Lyubov E. Larina https://doi.org/10.15690/pf.v22i2.2894
Abstract
Background. Glycogen Storage Disease Type Ib (GSDIb) is an inherited autosomal recessive orphan disease associated with a deficiency of the glucose—6-phosphate translocase transport protein and leading to excessive accumulation of glycogen in the liver and other organs. GSDIb occurs in about 20% of patients with type I glycogenosis and is characterized by a variety of manifestations, which makes diagnosis difficult.
Case report: A clinical example of early diagnosis of GSDIb in a 5-month-old boy with a burdened perinatal history is presented. The disease was suspected due to the presence of persistent neutropenia and hypoglycemia in the child, as well as recurrent bacterial infections. Whole-exome sequencing was performed, on the basis of which the diagnosis was made: “GSDIb caused by variants in the SLC37A4 gene: c.1108_1109delCT p.Leu370fs and c.85A>G p.Lys29Glu in a compound heterozygous state”.
Conclusion. The presented case report highlights the need for early diagnosis of GSDIb. This will allow timely initiation of specific therapy and improve the prognosis for patients with this disease.
Keywords
case report,
glycogen storage disease type Ib,
early diagnosis,
neutropenia,
hypoglycemia,
recurrent bacterial infections
Supporting agencies: Not specified
About the Authors
Nikol P. Shimkova
Pirogov Russian National Research Medical University
Russian Federation
Disclosure of interest:
Russian Federation
Nikol P. Shimkova - student.
1, Ostrovityanova Str., building 7, Moscow, 117997
Disclosure of interest:
Not declared
Mariya A. Snegurenko
Pirogov Russian National Research Medical University
Russian Federation
Disclosure of interest:
Russian Federation
Maria A. Snegurenko - student.
Moscow
Disclosure of interest:
Not declared
Eva Yunkevich
Pirogov Russian National Research Medical University
Russian Federation
Disclosure of interest:
Russian Federation
Eva Yunkevich - student.
Moscow
Disclosure of interest:
Not declared
Nataliya V. Klimina
Morozov Children’s City Clinical Hospital
Russian Federation
Disclosure of interest:
Russian Federation
Natalia V. Klimina – MD.
Moscow
Disclosure of interest:
Not declared
Anastasiya A. Shepina
Morozov Children’s City Clinical Hospital
Russian Federation
Disclosure of interest:
Russian Federation
Anastasia A. Shepina - MD.
Moscow
Disclosure of interest:
Not declared
Lyubov E. Larina
Pirogov Russian National Research Medical University
Russian Federation
Disclosure of interest:
Russian Federation
Liubov E. Larina - MD, PhD.
Moscow
Disclosure of interest:
Not declared
References
1. Glikogenovaya bolezn’ u detei: Clinical guidelines. Union of Pediatricians of Russia. Ministry of Health of Russian Federation; 2016. 53 p. (In Russ).
2. Surkov AN, Baranov AA, Namazova-Baranova LS, et al. Glycogen storage disease type Ib: modern understanding of the pathogenesis of neutropenia and prospects for its treatment with empagliflozin. Pediatricheskaya farmakologiya — Pediatric pharmacology. 2023;20(5):498–506. (In Russ). doi: https://doi.org/10.15690/pf.v20i5.2646
3. Dale DC, Bolyard AA, Marrero T, et al. Neutropenia in glycogen storage disease Ib: outcomes for patients treated with granulocyte colony-stimulating factor. Curr Opin Hematol. 2019;26(1):16–21. doi: https://doi.org/10.1097/MOH.0000000000000474
4. Gimaev IA, Bondar VA, Lushnikova EY, et al. Glycogen-storage disease type 1: medical and social alertnes. Medical and Social Expert Evaluation and Rehabilitation. 2020;23(1):57–62. (In Russ). doi: https://doi.org/10.17816/MSER34225
5. Baranov AA, Namazova-Baranova LS, Surkov AN, et al. Management of Children with Glycogen Storage Disease (Liver Involvement Forms). Best Practice Guidelines. Pediatricheskaya farmakologiya — Pediatric pharmacology. 2020;17(4):303–317. doi: https://doi.org/10.15690/pf.v17i4.2159
6. Gümüş E, Özen H. Glycogen storage diseases: An update. World J Gastroenterol. 2023;29(25):3932–3963. doi: https://doi.org/10.3748/wjg.v29.i25.3932
7. Leuzzi R, Bánhegyi G, Kardon T, et al. Inhibition of microsomal glucose-6-phosphate transport in human neutrophils results in apoptosis: a potential explanation for neutrophil dysfunction in glycogen storage disease type 1b. Blood. 2003;101(6):2381–2387. doi: https://doi.org/10.1182/blood-2002-08-2576
8. Dababneh R, Shawabkeh A, Gharaibeh S, et al. Periodontal Manifestation of Type Ib Glycogen Storage Disease: A Rare Case Report. Clin Adv Periodontics. 2020;10(3):150–154. doi: https://doi.org/10.1002/cap.10112
9. Saltik-Temizel IN, Koçak N, Ozen H, et al. Inflammatory bowel disease-like colitis in a young Turkish child with glycogen storage disease type 1b and elevated platelet count. Turk J Pediatr. 2005;47(2):180–182.
10. Gautier SV, Tsirulnikova OM, Mnatsakanyan DS, et al. Liver transplantation in children with glycogen storage diseases: risk assessment and necessity of this procedure. Russian Journal of Transplantology and Artificial Organs. 2013;15(1):67–74. (In Russ). doi: https://doi.org/10.15825/1995-1191-2013-1-67-74]
11. Martin AP, Bartels M, Schreiber S, et al. Successful staged kidney and liver transplantation for glycogen storage disease type Ib: A case report. Transplant Proc. 2006;38(10):3615–3619. doi: https://doi.org/10.1016/j.transproceed.2006.10.160
12. Visser G, Rake JP, Labrune P, et al. Consensus guidelines for management of glycogen storage disease type 1b — European Study on Glycogen Storage Disease Type 1. Eur J Pediatr. 2002;161(Suppl 1):S120–S123. doi: https://doi.org/10.1007/s00431-002-1017-6
13. Visser G, Rake JP, Fernandes J, et al. Neutropenia, neutrophil dysfunction, and inflammatory bowel disease in glycogen storage disease type Ib: results of the European Study on Glycogen Storage Disease type I. J Pediatr. 2000;137(2):187–191. doi: https://doi.org/10.1067/mpd.2000.105232
14. Wortmann SB, Van Hove JLK, Derks TGJ, et al. Treating neutropenia and neutrophil dysfunction in glycogen storage disease type Ib with an SGLT2 inhibitor. Blood. 2020;136(9):1033–1043. doi: https://doi.org/10.1182/blood.2019004465
15. Rossi A, Miele E, Fecarotta S, et al. Crohn disease-like enterocolitis remission after empagliflozin treatment in a child with glycogen storage disease type Ib: a case report. Ital J Pediatr. 2021;47(1):149. doi: https://doi.org/10.1186/s13052-02101100-w
16. Yiu WH, Pan CJ, Allamarvdasht M, et al. Glucose-6-phosphate transporter gene therapy corrects metabolic and myeloid abnormalities in glycogen storage disease type Ib mice. Gene Ther. 2007;14(3):219–226. doi: https://doi.org/10.1038/sj.gt.3302869
Review
For citations:
Shimkova N.P., Snegurenko M.A., Yunkevich E., Klimina N.V., Shepina A.A., Larina L.E. Glycogen Storage Disease Type Ib in the Compound Heterozygous State: Case Report. Pediatric pharmacology. 2025;22(2):178-183. (In Russ.) https://doi.org/10.15690/pf.v22i2.2894
Views:
156
Email this article 